ストックスクリーナーアプリを入手
2.67
5.32%
-0.15
X 4 Pharmaceuticals Inc (XFOR) 最新ニュース
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 27.1% in May - Defense World
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association - MarketScreener
Unicycive Sets 1-for-10 Reverse Split: What This Means for 126M Outstanding Shares - Stock Titan
XFOR Presents Positive Phase 2 Trial Results for Mavorixafor at EHA Congress | XFOR Stock News - GuruFocus
X4 Pharmaceuticals presents positive data from neutropenia trial By Investing.com - Investing.com Canada
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA) - marketscreener.com
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
Fierce Biotech Layoff Tracker 2025: ADC Tx lets go of 30% of workers; Vertex sheds 125 staffers - Fierce Biotech
Brokers Offer Predictions for XFOR FY2026 Earnings - Defense World
X4 Pharmaceuticals Elects New Director at Annual Meeting - TipRanks
X4 Pharmaceuticals Grants Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA - marketscreener.com
X4 Pharmaceuticals Granted Fast Track Designation For Mavorixafor For Treatment Of Chronic Neutropenia By US FDA - MarketScreener
X4 Pharmaceuticals gains on fast-track designation for mavorixafor for treatment of chronic neutropenia - MSN
X4 Pharmaceuticals (XFOR) Gains FDA Fast Track Status for Mavorixafor | XFOR Stock News - GuruFocus
FDA grants fast track status to X4’s neutropenia drug - Investing.com
X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - Quantisnow
Stock split by pharma company: Record date this week; Rs 297 crore order windetails - ET Now
Director Dugan Richard W was granted 59,225 shares, increasing direct ownership by 50% to 177,454 units (SEC Form 4) - Quantisnow
Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Why Skyrocketed Recursion Pharmaceuticals, Inc. (RXRX) Today - Insider Monkey
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format - The Manila Times
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XFOR Stock News - GuruFocus
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Investors Still Aren't Entirely Convinced By Phathom Pharmaceuticals, Inc.'s (NASDAQ:PHAT) Revenues Despite 54% Price Jump - simplywall.st
Bankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 million - AOL.com
Top 10 pharma companies in India by market cap [2025] - Forbes India
Director Moos Walter H was granted 2,500 shares, increasing direct ownership by 24% to 12,722 units (SEC Form 4) - Quantisnow
Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow
ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing - GlobeNewswire
Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028 - Benzinga
Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee - Yahoo Finance
X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 4% – Here’s Why - Defense World
SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Twinbeech Capital LP - MarketBeat
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares - Yahoo Finance
President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow
President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow
23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million - The New York Times
Bankrupt 23andMe Expected to Be Purchased for $256M - People.com
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - Quantisnow
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Waters Corp's India business boosted by rush for weight-loss drugs - Reuters
X4 Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Chronic Neutropenia Trial Data At The 30Th Annual Eha Congress - marketscreener.com
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress - marketscreener.com
X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data At the 30Th Annual Eha Congress - marketscreener.com
Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
What to Know About Eli Lilly’s Daily Pill for Weight Loss - The New York Times
HC Wainwright Raises X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $7.00 - Defense World
Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow
1.86%
1.98%
大文字化:
|
ボリューム (24 時間):